))
051: Ada Le and Mousumi Sannigrahi on behavioural science in healthcare
Manage episode 404797533 series 3556050
Conteúdo fornecido por Daniel Ross and Dan Biggar, Daniel Ross, and Dan Biggar. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Daniel Ross and Dan Biggar, Daniel Ross, and Dan Biggar ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
This week we’re diving into healthcare; what could be more critical? To help me understand how behavioural science is impacting this field, I’m joined by Dr. Ada Le, healthcare expert at BEworks and Dr. Mousumi Sannigrahi, newly installed as Head of Commercial for Innovative Medicines at Fosun Pharma US, having spent the last 8 years at Novartis Pharma.
Show notes
- What’s happening at the intersection of behavioural science and the pharma industry?
- How behavioural science plays out at Fosun vs. Novartis
- The next frontier for healthcare and behavioural science
- What needs to happen to move to a more human-centric approach to healthcare?
- The goal of the 1% Steps for Health Care Reform Project
- What are easy wins that the pharma industry can enact now?
- Psychological barriers for patients with autoimmune disease
- Rosy retrospection bias and failure to prescribe the right treatment
- David Robson and expectation effects: how mindset can alter our lives
- Dan Ariely’s end of life theories and research
- The scientific method of problem solving vs. more subtle placebo effects
- Hopes for healthcare in the next year
Please leave a review if you like the podcast; and share with friends. Your support makes us very happy!
79 episódios
Compartilhar
